Abigail Brooks, MA

The expanded label includes use in patients with PFIC 12 months of age and older as well as a higher concentration formulation.

The nomogram was constructed using independent risk factors for early cirrhosis and demonstrated greater diagnostic accuracy than current noninvasive fibrosis tests.

The homogenous genotyping test combines allele-specific tailed primers with SYBR-Green to facilitate fast and accurate detection of PI*S and PI*Z alleles of SERPINA1.

Integrating serum C3 and C4 levels into existing prognostic scores led to better prediction accuracy and may help optimize risk stratification in patients with IgAN.

Primary care patients with MASLD who received a prescription for moderate- and high-intensity statins had a lower risk of progressing to a high-risk FIB-4 score.

Spigler provides insight into the development of new patient-focused guidelines for managing hyperkalemia in CKD and the importance of providing patients with such resources.

Data from INSPIRE and COMMAND were used to support risankizumab’s FDA approval for ulcerative colitis, demonstrating the IL-23 inhibitor’s impact on clinical remission.

The analysis of NHANES data found individuals with viral hepatitis and NAFLD as well as lower income and no college education were at a greater risk of mortality.

The novel potassium-competitive acid blocker now boasts 3 FDA approvals across erosive and non-erosive GERD, expanding the treatment armamentarium for patients and clinicians.

Vonoprazan (Voquezna), the first major innovation in GERD treatment in more than 30 years, is now FDA-approved for both erosive and non-erosive GERD.

Announced on July 18, 2024, the FDA approval for heartburn relief associated with non-erosive GERD is based on the phase 3 PHALCON-NERD-301 trial.

The cross-sectional analysis found Medicaid nonexpansion status, fibrosis, and sobriety restrictions negatively impacted annual rates of DAA prescription fills.

Findings highlight an increased risk of diabetes, MASLD, and cardiovascular disease in patients with PCOS, with risk varying by PCOS phenotype.

Levinthal explains recent advances in the understanding of CVS and how the AGA clinical practice update reflects new information about its diagnosis and management.

A clinical practice update from the American Gastroenterological Association is providing clinicians with an overview of the diagnosis and management of CVS.

An analysis of data from the NV-HOPE study calls attention to lower rates of HBV and HCV screening among low-income US veterans versus the general US veteran population.

The high diagnostic and prognostic application values of newer IgAN machine learning models suggest their eventual utility in clinical practice.

Neuen explains the cardiovascular and kidney benefits of combining SGLT2 inhibitors and GLP-1 receptor agonists in diabetes and the future of combination therapy.

The patient-focused guidelines were developed by the American Kidney Fund and AstraZeneca to help people with CKD manage high potassium.

Low total, direct, and indirect bilirubin were linked to worsened IgAN-related clinical parameters, with reduced total and indirect bilirubin also identified as predictors of IgAN progression.

Refusal of hospital-administered birth doses of the hepatitis B vaccine declined in Washington, DC, from 2017-2022 despite pandemic-related disruptions to other childhood vaccines.

Findings suggest greater CTSS levels are associated with an elevated risk of IgAN and highlight the enzyme’s potential as a diagnostic biomarker.

Findings underscore the importance of HCC screening adherence in patients with HCV-related cirrhosis who achieve HCV cure for improving overall survival.

Findings from a phase 2b study demonstrate fazirsiran’s dose-dependent impact on Z-AAT concentrations and histological measures of liver disease in patients with AATD.

Findings from a meta-analysis examining 12 trials including more than 70,000 patients with diabetes support combining SGLT2 inhibitors and GLP-1 RAs.

Gross hematuria due to infection was not associated with the incidence of gross hematuria due to vaccination in patients with IgAN who received COVID-19 mRNA vaccination.

Compared to individuals with the PI*ZZ genotype, those with PI*SS had a lower risk of lung disease, increased lung function, and better quality of life.

Chehade reviews key findings from the phase 3 EoE kids trial and how they inform dupilumab’s use in children 1-11 years of age with eosinophilic esophagitis.

Patients with chronic tonsillitis had greater IgAN event rates than those without, and further analysis revealed chronic tonsillitis was linked to a greater risk of developing IgAN.

The June 2024 gastroenterology month in review highlights FDA news and other pipeline developments in GI as well as the publication of the latest installment of Qazi Corner.